Relationship between the Expression of Matrix Metalloproteinase and Clinicopathologic Features in Oral Squamous Cell Carcinoma

Document Type: Original


1 Cancer Molecular Research Center, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Solid Tumour Treatment Research Center, Omid Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Department of Anatomicoclinical Pathology, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences Mashhad, Iran.


Squamous cell carcinoma of the oral cavity is one of the most important and common types of head and neck malignancy, with an estimated rate of 4% among all human malignancies. The aim of this study was to determine the association between expression of matrix metalloproteinase 2 and 9 and the clinicopathological features of oral squamous cell carcinoma (OSCC).
Materials and Methods:
One hundred existing samples of formalin-fixed paraffin embedded specimens of OSCC were evaluated by immunohistochemistry staining for matrix metalloproteinase 2 and 9 antibodies. Samples were divided into four groups: negative, <10%, 10–50%, and >50%. Patient records were assessed for demographic characteristics such as age and gender, smoking and family history of OSCC as well as tumor features including location, differentiation, stage and lymph node involvement.
In this study, 58 patients (58%) were male and 42 (42%) female. The mean age of patients was 60.38±14.07 years. The average number of lymph nodes involved was 8.9±3.8. Tumoral grade, tumoral stage, lymphatic metastasis and history of smoking were significantly related to MMP2 and MMP9 expression.
Our study demonstrated that MMP2 and MMP9 expression are important in the development of OSCC.


Main Subjects

1. Hutchison I. Improving the prognosis of oral squamous cell carcinoma in 2013. Br Dent J 2013; 215(9):441.

2. Raj LSM, Boaz K, Natarajan S. Prognostic Significance of Lymph Node Pattern in Oral Squamous Cell Carcinoma (OSCC). J Clin Diagn Res 2014; 8(1):232–5.

3. Majchrzak E, Szybiak B, Wegner A, Pienkowski P, Pazdrowski J, Luczewski L, et al. Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature. Radiol Oncol 2014; 48(1):1–10.

4. Verma R, Hansch H. Matrix metalloproteinases (MMPs): Chemical–biological functions and (Q) SARs. Bioorg and Med Chem 2005;15:2223–68.

5. Marchenko G, Ratnikov B, Rozanov D, Godzik A, Deryugina E, Strongin A. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J 2001; 356: 705–18.

6. Oliveira LR, Castilho-Fernandes A, Oliveira-Costa JP, Soares FA, Zucoloto S, Silva AR.  CD44+/CD133+ immunophenotype and matrix metalloproteinase-9: Influence on prognosis in early-stage oral squamous cell carcinoma. Head Neck 2014;36(12):1718-26.

7. Jordan RC, Macabeo-Ong M, Shiboski CH, Dekker N, Ginzinger D, Wong DW, Schmidt BL. Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res 2004; 10(19):6460–5.

8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Review 2002; (2):161–74.

9. Mäkinen LK, Häyry V, Hagström J, Sorsa T, Santos FP, Santti HK, et al. Matrix metalloproteinase-7 and matrix metalloproteinase-25 in oral  tongue squamous cell carcinoma. Head Neck. 2013; 36(12): 1783-88. Nov 1. doi: 10.1002/hed.23539. [Epub ahead of print].

10. Lee HJ, Kim JW. Immunohistochemical study on the expression of matrix metalloproteinase 2 and high-risk human papilloma virus in the malignant progression of papillomas. J Korean Assoc Oral Maxillofac Surg 2013; 39(5):224–30. 

11. de Vicente JC, Fresno MF, Villalain L. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol 2005; 41(3):283–93.

12. Pereira AC, Dias do Carmo E, Dias da Silva MA, Blumer Rosa LE. Matrix metalloproteinase gene polymorphisms and oral cancer. J Clin Exp Dent 2012; 4(5):e297–e301.

13. Tamamura R, Nagatsuka H, Siar CH, Comparative analysis of basal lamina type IV collagen α chains, matrix metalloproteinases-2 and -9 expressions in oral dysplasia and invasive carcinoma. Acta Histochem 2012 11. [Epub ahead of print]

14. Mashhadiabbas F, Mahjour F, Mahjour SB, Fereidooni F, Hosseini FS. The immunohistochemical characterization of MMP-2, MMP-10, TIMP-1, TIMP-2, and podoplanin in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114(2):240–50.

15. Katayama A, Bandoh N, Kishibe K. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 2004; 10(2):634–40.

16. Fang J,Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G.Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci 2000; 97(8):3884–9.